3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
5
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Unknown Primary
2
Lung Neoplasms
2
Carcinoma
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unresectable Stage III NSCLC
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
First-line Advanced NSCLC Patients
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Endocrine System Diseases
1
Interventions
Gemcitabine
6
Trastuzumab
4
Carboplatin
3
pembrolizumab
2
Pemetrexed
2
Paclitaxel
2
Cisplatin
2
vinflunine
1
tucatinib
1
relatlimab
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
montanide ISA 51
1
flt3 ligand protein
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
apatorsen
1
abemaciclib
1
Zoledronic Acid
1
Urinary Diversion
1
Therapeutics
1
Thalidomide
1
Sunitinib
1
Radiosurgery
1
Nivolumab
1
Mitomycin
1
MART-1 Antigen
1
Immunoglobulins, Intravenous
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urologic Neoplasms
×
CP protocol
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled